The insider cluster is trivial and should not influence trading decisions. Focus on the GSK acquisition: monitor regulatory approval and tender process for Q3 2026 close. The $124/share offer represents a premium to recent trading levels.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 12 $123.25entry
- T+1 · 5mo ago +0.08%α −1.68% · $123.35
- T+5 · 5mo ago +0.15%α −0.53% · $123.43
- T+20 · 4mo ago +0.53%α −1.25% · $123.90
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Nuvalent insiders (CEO and Chief Development Officer) sold a combined ~$3.56M in open-market shares on June 8-9, 2026, alongside derivative exercises. The sales represent only ~0.04% of market cap and are routine option-exercise-related transactions. The dominant event is GSK's $10.6B acquisition of Nuvalent at $124/share, announced June 9, rendering these insider sales immaterial.
Key Financial Metrics
Key Facts
- CEO James Porter exercised 60,000 options (30k at $18.93, 30k at $0) and sold 12,495 shares for ~$1.10M on June 8.
- CDO Darlene Noci exercised 20,000 options (10k at $0, 10k at $1.08) and sold 20,000 shares for ~$2.46M on June 9.
- Total open-market sales: ~$3.56M, or 0.037% of Nuvalent's $9.7B market cap.
- GSK announced acquisition of Nuvalent for $124/share in cash on June 9, 2026, valuing equity at $10.6B.
- Insider sales occurred after the deal announcement and are consistent with routine option cash-outs, not informed selling.
Financial Impact
Insider sales of ~$3.56M are negligible relative to the $10.6B acquisition value and $9.7B market cap.
Risk Factors
- Regulatory or antitrust hurdles delaying or blocking the GSK acquisition.
- Shareholder approval or minimum tender condition not met.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NUVL-1781209982276 |
Track record
18 reports on NUVL
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 4 of 8 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Viewing Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers